FORTREA HOLDINGS INC (FTRE)
US34965K1079 - Common Stock
FTRE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of FTRE have multiple concerns. FTRE has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
FTRE had positive earnings in the past year.
FTRE had a positive operating cash flow in the past year.
1.2 Ratios
FTRE has a Return On Assets (-8.09%) which is in line with its industry peers.
FTRE has a Return On Equity of -19.75%. This is comparable to the rest of the industry: FTRE outperforms 49.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.09% | ||
| ROE | -19.75% | ||
| ROIC | N/A |
ROA(3y)2.22%
ROA(5y)N/A
ROE(3y)2.86%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
FTRE's Operating Margin has declined in the last couple of years.
FTRE has a worse Gross Margin (17.17%) than 85.45% of its industry peers.
FTRE's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for FTRE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 17.17% |
OM growth 3Y-10.89%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.06%
GM growth 5YN/A
2. Health
2.1 Basic Checks
FTRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
FTRE has more shares outstanding than it did 1 year ago.
The debt/assets ratio for FTRE is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.17, we must say that FTRE is in the distress zone and has some risk of bankruptcy.
FTRE has a Altman-Z score (1.17) which is in line with its industry peers.
FTRE has a debt to FCF ratio of 4.97. This is a neutral value as FTRE would need 4.97 years to pay back of all of its debts.
FTRE has a better Debt to FCF ratio (4.97) than 70.91% of its industry peers.
A Debt/Equity ratio of 0.77 indicates that FTRE is somewhat dependend on debt financing.
FTRE's Debt to Equity ratio of 0.77 is on the low side compared to the rest of the industry. FTRE is outperformed by 72.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 4.97 | ||
| Altman-Z | 1.17 |
ROIC/WACCN/A
WACC10.83%
2.3 Liquidity
A Current Ratio of 1.19 indicates that FTRE should not have too much problems paying its short term obligations.
FTRE's Current ratio of 1.19 is on the low side compared to the rest of the industry. FTRE is outperformed by 81.82% of its industry peers.
FTRE has a Quick Ratio of 1.19. This is a normal value and indicates that FTRE is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.19, FTRE is doing worse than 69.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.19 | ||
| Quick Ratio | 1.19 |
3. Growth
3.1 Past
The earnings per share for FTRE have decreased strongly by -101.76% in the last year.
FTRE shows a small growth in Revenue. In the last year, the Revenue has grown by 0.42%.
The Revenue has been growing slightly by 6.41% on average over the past years.
EPS 1Y (TTM)-101.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-583.23%
Revenue 1Y (TTM)0.42%
Revenue growth 3Y6.41%
Revenue growth 5YN/A
Sales Q2Q%-16.47%
3.2 Future
Based on estimates for the next years, FTRE will show a very strong growth in Earnings Per Share. The EPS will grow by 23.96% on average per year.
The Revenue is expected to grow by 3.09% on average over the next years.
EPS Next Y-58.76%
EPS Next 2Y-0.24%
EPS Next 3Y8.96%
EPS Next 5Y23.96%
Revenue Next Year-13.3%
Revenue Next 2Y-6.68%
Revenue Next 3Y-3.08%
Revenue Next 5Y3.09%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 54.17, which means the current valuation is very expensive for FTRE.
Compared to the rest of the industry, the Price/Earnings ratio of FTRE indicates a somewhat cheap valuation: FTRE is cheaper than 65.45% of the companies listed in the same industry.
FTRE is valuated expensively when we compare the Price/Earnings ratio to 28.96, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 14.76, the valuation of FTRE can be described as correct.
Based on the Price/Forward Earnings ratio, FTRE is valued cheaply inside the industry as 94.55% of the companies are valued more expensively.
FTRE is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.82, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.17 | ||
| Fwd PE | 14.76 |
4.2 Price Multiples
61.82% of the companies in the same industry are more expensive than FTRE, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, FTRE is valued cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.72 | ||
| EV/EBITDA | 65.7 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.24%
EPS Next 3Y8.96%
5. Dividend
5.1 Amount
FTRE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FORTREA HOLDINGS INC
NASDAQ:FTRE (11/21/2024, 8:00:01 PM)
After market: 19.39 -0.11 (-0.56%)19.5
+0.35 (+1.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.75B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.17 | ||
| Fwd PE | 14.76 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.09% | ||
| ROE | -19.75% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 17.17% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.19 | ||
| Quick Ratio | 1.19 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-101.76%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-58.76%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)0.42%
Revenue growth 3Y6.41%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y